RMC Advisory Committees

The following standing advisory committees report to the RMC:



This standing advisory committee advises the RMC on the recruitment and training of Highly Qualified Personnel (HQP). The AETOAC reviews and adjudicates applications for HQP program funding and recommends program investments that will increase the knowledge, skills and ability of HQP to conduct and apply cutting-edge research in the areas of allergy, asthma and related immune diseases. The work of this committee is informed by reports from the the AllerGen Students and New Professionals Network (ASNPN).

Committee Members

Richard Hegele (Chair)

Richard Hegele. MD, FRCPC, PhDhegele (Chair)

Vice-Dean, Research and Innovation; Professor and Chair, Laboratory Medicine & Pathobiology, University of Toronto; Clinical Chief of Department, Paediatric Laboratory Medicine, Hospital for Sick Children

Dr. Hegele has an extensive background and expertise in basic and translational research in viral and inflammatory diseases.

Fiona Brinkman

Fiona_BrinkmanlargeFiona Brinkman, PhD

Professor, Biology & Biochemistry, Simon Fraser University

Dr. Brinkman is a leader in the area of pathogen bioinformatics. Her current research centers on improving understanding of how pathogens and pathogenicity evolve and improving computational methods that aid the development of new vaccines, drugs and diagnostics for infectious diseases.

Thomas Issekutz

IssekutzThomas Issekutz, MD

Professor and Head, Division of Immunology, Department of Pediatrics, Dalhousie University

As a pediatric immunologist, Dr. Issekutz works with families who are struggling with ongoing complications of immune deficiency diseases. As a researcher and as a senior professor, he is determined to learn how and why these diseases develop.

Oxana Latycheva

LatychevaOxana Latycheva, PhD

Director, Primary Health Care, Parkdale Community Health Centre

Dr. Latycheva was formerly Vice-President of Asthma Control Programming for the Asthma Society of Canada and Manager of Clinical Systems Initiatives for the Ontario Lung Association.

Danuta Radzioch

danutaDanuta Radzioch, PhD

Professor, Departments of Medicine and Human Genetics, McGill University; Medical Scientist, Clinical Immunology, Montreal General Hospital

Dr Radzioch has expertise in molecular biology, host-pathogen interactions, mouse models and translational medicine.

Diana Royce

dianaroyceDiana Royce, EdD

Managing Director and COO, AllerGen NCE Inc.

Dr. Royce has over 30 years of experience in the post-secondary and health sectors related to public consultation and research, program implementation, strategic and operational planning, network administration, partnership and public policy development, advocacy, fundraising, knowledge mobilization, conference planning and meeting facilitation.

Amrit Singh


Amrit Singh, PhDAmirt

President, ASNPN

Dr. Singh is a post-doctoral fellow at the PROOF (Prevention of Organ Failure) Centre, working under Dr. Bruce McManus. He received his PhD in Experimental Medicine from The University of British Columbia in 2016.

Harissios Vliagoftis

harissios-vliagoftisHarissios Vliagoftis, MD

Professor and Director, Division of Pulmonary Medicine, Department of Medicine, University of Alberta

Dr. Vliagoftis’ laboratory focuses on understanding the mechanisms leading to allergic sensitization and allergic airway inflammation. In addition to his research, Dr. Vliagoftis is an active clinician and has worked to expand allergy services in Alberta.

Richard Warrington

warringtonRichard Warrington, PhD, FAAAAI, FRCP(C)

Professor, Department of Medicine, University of Manitoba

Dr. Warrington’s research has been on cytokines and autoantibodies and drug hypersensitivity. He is currently studying the effects of anti-cytokines antibodies in intravenous gammaglobulin.

Susan Waserman

dr-susan-wasermanSusan Waserman, MD, FRCP(C)

Professor Division of Clinical Immunology and Allergy, Department of Medicine, McMaster University; President, Canadian Allergy, Asthma and Immunology Foundation (CAAIF)

Dr. Waserman’s research interests and activities include clinical trials in a variety of therapeutic areas related to allergy, including rhinitis, asthma, as well as determinants of allergic expression in asthma and food-related anaphylaxis.



This standing advisory committee reports to both the RMC and the BoD and advises on the quality and innovativeness of the Network’s current and proposed research program. The ISEAC ensures that AllerGen-supported research and initiatives are at the leading edge of expertise and innovation, and are optimizing national and international opportunities for collaboration. It also performs external peer reviews, provides formative feedback on the Network’s research funding competitions, and contributes to the development of strategic priorities and plans.



This standing advisory committee reviews AllerGen’s knowledge and technology exchange and exploitation (KTEE) opportunities, plans, programs and initiatives. It provides funding and strategic advice to the RMC, and provides mentorship to Network investigators to support the development, protection, commercialization and financing of intellectual property arising from Network research results.

Committee Members

Diana Royce (Chair)

dianaroyceDiana Royce, EdD

Managing Director and COO, AllerGen NCE Inc.

Dr. Royce has over 30 years of experience in the post-secondary and health sectors related to public consultation and research, program implementation, strategic and operational planning, network administration, partnership and public policy development, advocacy, fundraising, knowledge mobilization, conference planning and meeting facilitation.

Dean Befus


Dean Befus, PhD

Professor, Division of Pulmonary Medicine, Department of Medicine, University of Alberta; Astra-Zeneca Canada Inc., Chair in Asthma Research

Dr. Befus focuses on finding new therapeutic treatments for asthma patients when their airways become inflamed by an asthma trigger, such as moulds, pollen and dust. He is director of the Alberta Asthma Centre and co-leader of AllerGen’s Biomarkers and Bioinformatics Enabling Platform.

Thierry Bourgeois

thierryThierry Bourgeois, M.Sc.A.

Adjoint au vice-recteur à la recherche et à la création and vice-rectorat à la création, Pavillon des Sciences de l’éducation, Université Laval

Thierry Bourgeois is Assistant to the Vice Rector and Director of the Community-University Liaison Office of Laval University.

Judah Denburg

jdsmallJudah Denburg, MD, FRCPC

Scientific Director and CEO, AllerGen NCE Inc.

As Scientific Director of AllerGen, Dr. Denburg helps steer an innovative and inter-disciplinary research program. Dr. Denburg’s main research thrusts include examination of the mechanisms of allergic inflammation, with particular emphasis on hemopoietic cytokines and their role in activating the differentiation and recruitment of inflammatory cells such as eosinophils, basophils and mast cells.

Sylviane Duval

Sylviane-DuvalSylviane Duval

Knowledge Transfer Specialist

Sylviane Duval launched her research communications and knowledge translation/transfer business in 2003 after working at McGill University and the Royal Architectural Institute of Canada. Her current clientele consists mostly of university research networks and knowledge-based organizations.

Neal Lemon

lemon-cropNeal Lemon, PhD, MBA

Associate Director Technology Licensing, University of Pennsylvania

Dr. Lemon assists faculty, staff and students with all aspects of technology transfer and commercialization, building new research and development collaborations with industry partners, managing all internal and external relationships with key stakeholders to fully enable technology commercialization.

Luc Marengère

lucLuc Marengère, PhD

Managing Partner, TVM Capital

Dr. Marengère oversees the establishment of new Canadian operations and the North American investment strategy for TVM Capital. He has over 15 years of previous venture capital experience in Canada and the U.S.

Daniel Nixon

nixonDaniel Nixon, MBA

Director & Chief Financial Officer, Molecular You Corporation

Mr. Nixon is a seasoned executive with extensive private equity, investment banking and operations experience.

Kevin O'Brien Fehr

kevinKevin O’Brien Fehr, PhD

Consultant, Kincora Innovation

Kevin O’Brien Fehr is a pharmacologist who, since 1992, has managed basic research and genetics studies conducted in Canadian companies and universities on behalf of GlaxoSmithKline.

Brian Underdown

pix_b-underdownBrian Underdown, PhD

Venture Partner, Lumira Capital

Dr. Underdown recently retired as Managing Director at Lumira Capital, in which position he managed investments in North American therapeutics companies at all stages of development. Previously, he was Assistant Vice-President for Research at Pasteur Merieux Connaught, where he headed the Canadian Universities Research program and several global programs to develop vaccines, and Associate Dean of Research at the University of Toronto’s Faculty of Medicine and at McMaster University’s Faculty of Health Sciences.

Randall W. Yatscoff

yatscoffRandall W. Yatscoff, PhD

Executive Vice-President – Business Development, TEC Edmonton

Dr. Yatscoff has spent the last six years at TEC Edmonton initially as an Alberta Heritage Foundation Medical Research Executive in Residence and more recently as Executive Vice-President of Business Development.